Simplify your research in cancer biology and discover new approaches to diagnosis with the new BOND RX next generation research stainer by Leica Biosystems. The BOND RX system provides researchers with the ability to design their ideal protocol. With customization options across all protocol editing segments, the BOND RX enables greater flexibility when optimizing conditions for a variety of test types including IF, ISH, FISH, TUNEL, TSA, CTC, Multiplexing and other emerging tests. Geared toward expanding the user’s freedom to discover, the latest advances to the BOND RX include enhancements to improve the overall user experience. Coupled with an expansion to the system’s customization capabilities, researcher’s now have more options to explore their ideas. Primary Features of the new BOND RX include:
• Protocol Customization Advancements
o Customize your dewax options. Add or subtract as many dewax steps as needed.
o Choose from six unique probe...
“With science advancing at such a rapid rate, it is an exciting time to be supporting researchers as they seek to unlock the complexity of cancer biology and develop new approaches to diagnosis” said Colin White, PhD Global Vice President – Advanced Staining at Leica Biosystems. “The release of the next generation of BOND RX is an important milestone in providing our customers with broader experimental flexibility and improved usability”. Leica Biosystems has an open system across the workflow and an optimized product portfolio that offers you the reproducibility and flexibility you need to uncover critical details. Spend less time on manual tasks and more time innovating to find answers – helping you obtain the data needed to secure funding for that next breakthrough discovery. The new BOND RX automated researcher stainer, featuring enhanced usability and increased protocol editing flexibility is available in USA.